Heparin catheter flush finds a home at CDRH
This article was originally published in The Gray Sheet
Executive Summary
Effective Oct. 16, the device center will assume primary responsibility for the regulation of heparin lock-flush solution products, some of which had been under the purview of the Center for Drug Evaluation and Research. The transfer of the combination product to CDRH reflects FDA's determination that the primary mode of action is that of the device, which is used to keep intravascular catheters open and prevent blood from clotting. Heparin lock-flush solution products will now be considered 510(k) products, and must comply with the device Quality System Regulation. FDA will not assess any application user fees for the administrative transfer...
You may also be interested in...
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.